Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 17Terminated 7Recruiting 5Active not recruiting 3Unknown 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Breast Neoplasms 3Uterine Cervical Neoplasms 1Tuberous Sclerosis 1Tongue Neoplasms 1Sturge-Weber Syndrome 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Port-Wine Stain 1Peutz-Jeghers Syndrome 1Neuroendocrine Tumors 1Neoplastic Processes 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Liver Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Glioma 1Glaucoma 1Epilepsy 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Renal Cell 1

Interventions

telotristat ethyl 3lutetium Lu 177 dotatate 33-Iodobenzylguanidine 3177Lu-octreotide, DOTA(0)-Tyr(3)- 2veliparib 1vandetanib 1gallium Ga 68 dotatate 1Tretinoin 1Temozolomide 1Isotretinoin 1Introns 1Everolimus 1Capecitabine 1177Lu-octreotate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Neuroendocrine Tumors × Everolimus × Clear all
NCT01864070 2014-07-22

Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease

M.D. Anderson Cancer Center

Phase 1 Withdrawn
EndocrineGastrointestinalNET

Liver Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡